Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

icated:

  • Results with R7128 500mg bid, 1000mg bid and 1500mg bid with SOC achieved a mean 3.8 log10 IU/mL (30% RVR, 6 of 20), 5.0 log10 IU/mL (88% RVR, 22 of 25) and 5.1 log10 IU/mL (85% RVR, 17 of 20) decrease in HCV RNA, respectively. Results with placebo with SOC indicated patients achieved a mean 2.9 log10 IU/mL decrease in HCV RNA and 18.75% (3 of 16) patients achieved RVR (<15 IU/ml).

In a harder to treat, non-responder, genotype 2 and 3 HCV patient population treated for 4 weeks:

  • Results with R7128 1500mg bid with SOC led to 90% of patients achieving an RVR (<15 IU/ml) compared to 60% in the standard of care arm.

In November 2008, Pharmasset, Roche and InterMune initiated the INFORM-1 trial to investigate the combination of R7128 with InterMune's R7227 (ITMN-191), a protease inhibitor in HCV patients in the absence of pegylated interferon and ribavirin. Patients will receive a maximum of 14 days of combination treatment, followed by Pegasys(R) plus Copegus(R) for a further 46 weeks. The aim of the study is to investigate the safety and antiviral activity of the combination.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
8. Pharmasset Joins Russell 3000 Index
9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management ... over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... 21, 2011 The report " ... Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 ... major market drivers, restraints, and opportunities in North America, ... tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic ...
... 18, 2011 Percentage of revenues from ... medical relief organization building a hospital in Ethiopia ... technical and medical information products and services, announced today ... (ICA) through its "Pillars of Hope" ...
... W.Va. Recent studies conducted at Marshall University have demonstrated ... used to increase the fuel efficiency of automobile engines -- ... this process is associated with liver damage. The ... his colleagues at Marshall,s Center for Diagnostic Nanosystems indicate there ...
Cached Biology Technology:MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver 2
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... College London has discovered 24 new genes that cause refractive ... major cause of blindness and visual impairment worldwide, and currently ... journal Nature Genetics , reveal genetic causes of the ... of preventing the condition in the future. ...
... roles in the same biological pathways change their rate of ... discover their functions, said a researcher at the University of ... GENETICS . Humans have nearly 21,000 genes that make ... genes have not been fully determined, said lead investigator Nathan ...
... and Germany have identified that the proteins lamin A ... holding silent genes in their correct position at the ... . A deviation from their normal position will cause ... disease and muscle wasting. 2. For hundreds of ...
Cached Biology News:New genes for short-sightedness identified 2Evaluating evolutionary rates could shed light into functions of uncharacterized genes 2A*STAR scientists' groundbreaking discovery of nucleus structure crucial to understanding diseases 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: